Crohn's Disease

Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17....

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel). The study demonstrated clinical remission in 65% of patients in both cohorts evaluated...

AbbVie Inc (NYSE: ABBV) announced topline results from U-EXCEED, a Phase 3 induction study, of upadacitinib (45 mg once daily) in Patients with Crohn's Disease. The data achieved both primary endpoints of clinical remission and endoscopic response at week 12.  The U-EXCEED...

Galapagos NV (NASDAQ: GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance of remission in patients with Crohn's Disease (CD). The DIVERSITY study enrolled 1,374 participants. The study evaluates the safety and...

Analysts have lowered the price target and downgraded Theravance Biopharma Inc (NASDAQ: TBPH) after disappointing ulcerative colitis Phase 2 trial data. Related: Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study Cowen downgraded Theravance Biopharma to Market...

Theravance Biopharma Inc's (NASDAQ: TBPH) Izencitinib, a "gut-selective" JAK inhibitor developed for ulcerative colitis and Crohn's disease, failed a key Phase 2 trial. Johnson & Johnson's (NYSE: JNJ) pharmaceutical unit Janssen dished out $100...

Cerecor Inc (NASDAQ: CERC) announced initial results from a Phase 1b proof-of-concept study evaluating CERC-002 in adult patients with moderate to severe Crohn's disease (CD). CERC-002 is an investigational fully human anti-LIGHT (tumor necrosis factor superfamily member 14 (...

AbbVie Inc (NYSE: ABBV) has announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing Skyrizi (risankizumab) achieved the co-primary endpoints of endoscopic response and clinical remission at one year in Crohn's disease. After one year, 47% of patients...

As a part of a pre-specified analysis of the Phase 2 SERENITY study, new data showed that Eli Lilly And Co's (NYSE: LLY) mirikizumab improved fatigue in patients with moderately to severely active Crohn's disease (CD) at 12 weeks. Improvements were sustained up to one...

The Janssen Pharmaceutical Companies, a unit of Johnson & Johnson (NYSE: JNJ), announced efficacy and safety data for Stelara (ustekinumab) in Crohn's disease (CD) and ulcerative colitis (UC), including data from the SEAVUE study, a head-to-head study of biologic therapies. Data...

Tucked in its Q1 earnings release, Eli Lilly And Co (NYSE: LLY) has scrapped its plans to seek approval for mirikizumab in psoriasis. The company decided not to enter the market despite the anti-IL-23p19 antibody outperforming Novartis AG’s (NYSE: NVS)...

REDHILL BIOPHAR/S ADR (NASDAQ: RDHL) achieved positive top-line results in its Phase 3 study of RHB-104 in Crohn’s disease, according to a Monday press release. What Happened The drug met both primary and secondary endpoints by demonstrating a remission rate superior to that of the placebo...

William Blair said in a note the double hit on Celgene Corporation (NASDAQ: CELG)'s Inflammation and Immunology franchise may have reversed positive sentiment, but the company's growth thesis and pipeline optionality remains intact. The firm reiterated its Outperform rating on the shares of the...

Celgene Corporation (NASDAQ: CELG) stock plummeted 10 percent Friday after the company reported that its testing of GED-0301 for treatment of Crohn’s disease has failed to meet its efficacy targets. A handful of Wall Street analysts weighed in on Celgene stock following the news. Here’s...